|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||12.56 / 47.98|
Watch the Russell 2000, housing activity, and mergers and acquisitions.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
The names include a veterinary drug concern plus companies with successful drugs on the market.
These two firms have successful drugs and could make nice additions for larger companies.
I'm inclined to add to Disney on today's weakness.
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
Experts offer their top stock ideas in oncology detection and treatment.
Leading up to potential FDA approvals can be particularly 'dicey' times for biotech investors.
A fresh look at all 17 ideas: the winners, the losers and the still to be determined.
Despite biotech losing a bit of its former headline grabbing attention, there are still plenty of great setups to be found.
I really like how these three charts are shaping up on Array.
The market isn't buying that Trump is bad for business
Such unwarranted fears have depressed the sector, which could bounce back after Nov. 8.
I'm even staying away from the appealing stocks.
Array is partnering with AstraZeneca and Novartis on a number of cancer drugs with trials soon getting underway that could transform the company by year end.
StockMarketMentor.com founder Dan Fitzpatrick details how to play three stocks Jim Cramer discussed on CNBC's "Mad Money" last night.
Portfolio manager David Peltier discusses a hot biotech stock with a promising clinical pipeline.
Senior columnist Adam Feuerstein says the ASCO Cancer Conference is the next big thing in biotech.